NASDAQ$SLNO
Soleno Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Soleno Therapeutics reported financial results for Q1 2024 and provided a corporate update.
Soleno Therapeutics reported a net loss of $21.4 million for the quarter ended March 31, 2024. The company's research and development efforts are primarily focused on advancing its lead product candidate, DCCR, for the treatment of PWS. As of March 31, 2024, Soleno had $42.8 million of cash and cash equivalents, $106.8 million of short-term investments, and $8.8 million of long-term investments.
- Closed on approximately $158.7 million underwritten public offering.
- Granted Breakthrough Therapy Designation by the FDA for DCCR for the treatment of adults and children ages four years and older with genetically confirmed Prader-Willi syndrome (PWS) who have hyperphagia.
- Planned submission of a New Drug Application (NDA) for DCCR in PWS remains on track for mid-2024.
- Strengthened leadership team with appointments of Meredith Manning, M.B.A. as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources.
Headline financials
Revenue & EPS history
Soleno Therapeutics · Revenue · Quarterly
$0
Forward guidance
The press release contains forward-looking statements regarding the timing of any regulatory process, filing of an NDA, or ultimate approvals and determining a path forward for DCCR for the treatment of PWS.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-1.8%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-0.6%
Avg return
30 days after
38%
18 / 48 earnings
Positive
+15.2%
Q4 2014
Best reaction
-26.4%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -0.0% | — | |
| Q4 2025 | -7.1% | -8.1% | -26.7% | |
| Q3 2025 | -26.4% | -27.5% | -19.5% | |
| Q2 2025 | -3.2% | +2.7% | -14.1% | |
| Q1 2025 | +2.2% | -0.3% | +1.1% | |
| Q4 2024 | -2.5% | +10.2% | +41.3% | |
| Q3 2024 | +1.3% | +4.9% | -12.8% | |
| Q2 2024 | -3.5% | +0.2% | +3.9% | |
| Q1 2024 | -2.7% | -6.0% | -1.5% | |
| Q4 2023 | -1.0% | -2.8% | -7.9% | |
| Q3 2023 | -5.1% | -4.8% | +60.1% | |
| Q2 2023 | +4.3% | -2.1% | -22.9% | |
| Q1 2023 | -3.6% | -1.2% | +42.9% | |
| Q4 2022 | +3.0% | +16.3% | +87.6% | |
| Q3 2022 | +2.9% | +5.2% | -6.2% | |
| Q2 2022 | +12.7% | +11.0% | -16.2% | |
| Q1 2022 | -6.5% | +10.5% | +12.1% | |
| Q4 2021 | -3.7% | +4.9% | -8.2% | |
| Q3 2021 | -0.8% | -1.9% | -21.4% | |
| Q2 2021 | +3.8% | +4.7% | -0.8% | |
| Q1 2021 | -7.8% | -6.1% | -1.7% | |
| Q4 2020 | +0.0% | -47.5% | -50.2% | |
| Q3 2020 | -4.0% | +3.5% | -6.5% | |
| Q2 2020 | +6.1% | +4.5% | +20.7% | |
| Q1 2020 | -5.0% | -3.2% | -48.2% | |
| Q4 2019 | +13.0% | +1.1% | -21.1% | |
| Q3 2019 | +10.7% | +6.4% | +34.3% | |
| Q2 2019 | -0.5% | +3.1% | -4.6% | |
| Q1 2019 | -4.1% | -4.1% | +41.2% | |
| Q4 2018 | -14.9% | -10.3% | -26.5% | |
| Q3 2018 | +1.0% | -4.3% | -22.6% | |
| Q2 2018 | -4.3% | -5.1% | -20.4% | |
| Q1 2018 | +3.1% | +8.6% | +29.8% | |
| Q4 2017 | -0.7% | +1.5% | -9.0% | |
| Q3 2017 | -13.6% | -22.7% | -17.9% | |
| Q2 2017 | +8.6% | -6.2% | +28.4% | |
| Q1 2017 | +7.2% | +1.4% | -14.5% | |
| Q4 2016 | +6.3% | +0.1% | -14.7% | |
| Q3 2016 | -0.8% | +0.0% | -17.5% | |
| Q2 2016 | -5.1% | -2.4% | +8.6% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | -9.1% | — | — | |
| Q3 2015 | -3.7% | — | — | |
| Q2 2014 | -14.1% | — | — | |
| Q2 2015 | -14.2% | — | — | |
| Q1 2015 | -14.3% | — | — | |
| Q4 2014 | +15.2% | — | — | |
| Q3 2014 | +0.6% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro